1,25-Dihydroxyvitamin D to PTH(1-84) ratios strongly predict cardiovascular death in heart failure

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Gruson, Damien ^a   Ferracin, Benjamin ^a   Ahn, Sylvie A ^a   Zierold, Claudia ^b   Blocki, Frank ^b   Hawkins, Douglas M ^c   Bonelli, Fabrizio ^b   Rousseau, Michel F ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Diasorin SpA   (Italy)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; PARATHYROID HORMONE; 1,25-DIHYDROXYVITAMIN D; VITAMIN D;

ADULT; AGED; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; SURVIVAL; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; CHRONIC DISEASE; MIDDLE AGED; MORTALITY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROGNOSIS; VITAMIN D; YOUNG ADULT;

EID: 84942904540     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135427     Document Type: Article

References (56)

1. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J 2014 Nov 7; 35(42):2950-9. doi: 10.1093/eurheartj/ehu299 PMID: 25139896
2. Liu LC, Damman K, Lipsic E, Maass AH, Rienstra M, Westenbrink BD. Heart failure highlights in 2012-2013. Eur J Heart Fail 2014 Feb; 16(2):122-32. doi: 10.1002/ejhf.43 PMID: 24464645
3. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation 2000 Nov 14; 102(20 Suppl 4):IV14-IV23. PMID: 11080127
4. Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013 Jun 5;(13: ):10.
5. Januzzi JL Jr., Chen-Tournoux AA, Moe G. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol 2008 Feb 4; 101 (3):29-38. doi: 10.1016/j.amjcard.2007.11.017 PMID: 18243855
6. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J 2014 Aug;%19. pii: ehu299.:ehu299.
7. Mueller C. Cost-effectiveness of B-type natriuretic peptide testing. Congest Heart Fail 2008 Jul; 14(4 Suppl 1):35-7. PMID: 18772637
8. Roubille F, Delseny D, Cristol JP, Merle D, Salvetat N, Larue C, et al. Depletion of proBNP1-108 in patients with heart failure prevents cross-reactivity with natriuretic peptides. PLoS One 2013 Sep 17; 8 (9):e75174. doi: 10.1371/journal.pone.0075174 PMID: 24069392
9. Savarese G, Trimarco B, Dellegrottaglie S, Prastaro M, Gambardella F, Rengo G, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One 2013; 8(3):e58287. doi: 10.1371/journal.pone.0058287 PMID: 23472172
10. Maisel A, Mueller C, Adams K Jr., Anker SD, Aspromonte N, Cleland JG, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008 Sep; 10(9):824-39. doi: 10.1016/j. ejheart.2008.07.014 PMID: 18760965
11. Emdin M, Vittorini S, Passino C, Clerico A. Old and new biomarkers of heart failure. Eur J Heart Fail 2009 Apr; 11(4):331-5. doi: 10.1093/eurjhf/hfp035 PMID: 19329823
12. Volpe M, Rubattu S, Burnett J Jr. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J 2013 Nov 13.
13. de Boer RA, Lok DJ, Jaarsma T, Van Der Meer P, Voors AA, Hillege HL, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011 Feb; 43(1):60-8. doi: 10.3109/07853890.2010.538080 PMID: 21189092
14. Gruson D, Buglioni A, Burnett JC Jr. PTH: Potential role in management of heart failure. Clin Chim Acta 2014 Jun 10; 433:290-6. doi: 10.1016/j.cca.2014.03.029 Epub;%2014 Apr 1.:290-6. PMID: 24704306
15. Tunon J, Cristobal C, Tarin N, Acena A, Gonzalez-Casaus ML, Huelmos A, et al. Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease. PLoS One 2014 Apr 18; 9(4):e95402. doi: 10.1371/journal.pone.0095402 PMID: 24748388
16. Schierbeck LL, Jensen TS, Bang U, Jensen G, Kober L, Jensen JE. Parathyroid hormone and vitamin D-markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail 2011 Jun; 13 (6):626-32. doi: 10.1093/eurjhf/hfr016 PMID: 21415099
17. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008 Jan 29; 117(4):503-11. doi: 10.1161/ CIRCULATIONAHA.107.706127 PMID: 18180395
18. Tomaschitz A, Ritz E, Pieske B, Fahrleitner-Pammer A, Kienreich K, Horina JH, et al. Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. Cardiovasc Res 2012 Apr 1; 94 (1):10-9. doi: 10.1093/cvr/cvs092 PMID: 22334595
19. Silver J, Rodriguez M, Slatopolsky E. FGF23 and PTH-double agents at the heart of CKD. Nephrol Dial Transplant 2012 May; 27(5):1715-20. doi: 10.1093/ndt/gfs050 PMID: 22447519
20. Udell JA, Morrow DA, Jarolim P, Sloan S, Hoffman EB, O'Donnell TF, et al. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol 2014 Jun 10; 63(22):2421-8. doi: 10.1016/j.jacc.2014.03.026 PMID: 24727254
21. Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 2014 May; 10(5):268-78. doi: 10.1038/nrneph.2014.49 PMID: 24686452
22. van HJ, Weiskirchen R. Experience with the first fully automated chemiluminescence immunoassay for the quantification of 1alpha, 25-dihydroxy-vitamin D. Clin Chem Lab Med 2014 Sep 30;j/cclm-print/ cclm.
23. Renkema KY, Alexander RT, Bindels RJ, Hoenderop JG. Calcium and phosphate homeostasis: concerted interplay of new regulators. Ann Med 2008; 40(2):82-91. doi: 10.1080/07853890701689645 PMID: 18293139
24. Keyzer CA, Riphagen IJ, Joosten MM, Navis G, Muller Kobold AC, Kema IP, et al. Associations of 25 (OH) and 1,25(OH) Vitamin D with Long-Term Outcomes in Stable Renal Transplant Recipients. J Clin Endocrinol Metab 2014 Oct 31;jc20143012.
25. Zittermann A, Schleithoff SS, Frisch S, Gotting C, Kuhn J, Koertke H, et al. Circulating calcitriol concentrations and total mortality. Clin Chem 2009 Jun; 55(6):1163-70. doi: 10.1373/clinchem.2008.120006 PMID: 19359534
26. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab 2010 Feb; 95(2):471-8. doi: 10. 1210/jc.2009-1773 PMID: 20133466
27. Zittermann A, Schleithoff SS, Gotting C, Dronow O, Fuchs U, Kuhn J, et al. Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail 2008 Mar; 10(3):321-7. doi: 10.1016/j.ejheart.2008.01.013 PMID: 18304873
28. Gotsman I, Shauer A, Zwas DR, Hellman Y, Keren A, Lotan C, et al. Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. Eur J Heart Fail 2012 Apr; 14(4):357-66. doi: 10.1093/eurjhf/hfr175 PMID: 22308011
29. Wannamethee SG, Welsh P, Papacosta O, Lennon L, Whincup PH, Sattar N. Elevated parathyroid hormone, but not vitamin D deficiency, is associated with increased risk of heart failure in older men with and without cardiovascular disease. Circ Heart Fail 2014 Sep; 7(5):732-9. doi: 10.1161/ CIRCHEARTFAILURE.114.001272 PMID: 25104043
30. di Giuseppe R, Buijsse B, Hirche F, Wirth J, Arregui M, Westphal S, et al. Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: a prospective, case-cohort study. J Clin Endocrinol Metab 2014 Mar; 99(3):947-55. doi: 10.1210/jc.2013-2963 PMID: 24423292
31. Eknoyan G. Adolphe Quetelet (1796-1874)-the average man and indices of obesity. Nephrol Dial Transplant 2008 Jan; 23(1):47-51. PMID: 17890752
32. Gruson D, Lepoutre T, Ahn SA, Ketelslegers JM, Rousseau MF. Comparison between intact and bioactive parathyroid hormone assays in patients with severe heart failure. Clin Biochem 2013 Mar; 46(4-5):391-4. doi: 10.1016/j.clinbiochem.2012.12.002 PMID: 23246538
33. Altay H, Zorlu A, Binici S, Bilgi M, Yilmaz MB, Colkesen Y, et al. Relation of serum parathyroid hormone level to severity of heart failure. Am J Cardiol 2012 Jan 15; 109(2):252-6. doi: 10.1016/j.amjcard.2011. 08.039 PMID: 21996143
34. Khouzam RN, Dishmon DA, Farah V, Flax SD, Carbone LD, Weber KT. Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure. Am J Med Sci 2006 Jan; 331(1):30-4. PMID: 16415661
35. Gruson D, Lepoutre T, Ahn SA, Ketelslegers JM, Rousseau MF. Increased circulating concentrations of bioactive PTH 1-84 in patients with heart failure. J Endocrinol Invest 2012 Dec; 35(11):987-91. doi: 10.3275/8286 PMID: 22391109
36. Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003 Nov; 24(22):2054-60. PMID: 14613742
37. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 2005 Feb 22; 111(7):871-8. PMID: 15710759
38. Rutledge MR, Farah V, Adeboye AA, Seawell MR, Bhattacharya SK, Weber KT. Parathyroid hormone, a crucial mediator of pathologic cardiac remodeling in aldosteronism. Cardiovasc Drugs Ther 2013 Apr; 27(2):161-70. doi: 10.1007/s10557-012-6378-0 PMID: 22373564
39. Vidal A, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, Weber KT. Calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol 2006 Jan; 290(1):H286-H294. PMID: 16373592
40. Lysaght AC, Yuan Q, Fan Y, Kalwani N, Caruso P, Cunnane M, et al. FGF23 deficiency leads to mixed hearing loss and middle ear malformation in mice. PLoS One 2014 Sep 22; 9(9):e107681. doi: 10.1371/ journal.pone.0107681 PMID: 25243481
41. Razzaque MS. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009 Nov; 5(11):611-9. doi: 10.1038/nrendo.2009.196 PMID: 19844248
42. Bernheim J, Benchetrit S. The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases. Nephrol Dial Transplant 2011 May 4.
43. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010 May 18; 152(10):640-8. doi: 10.7326/ 0003-4819-152-10-201005180-00004 PMID: 20479029
44. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009 May;%19; 119 (19):2545-52. doi: 10.1161/CIRCULATIONAHA.108.844506 PMID: 19414634
45. Gruson D, Lepoutre T, Ketelslegers JM, Cumps J, Ahn SA, Rousseau MF. C-terminal FGF23 is a strong predictor of survival in systolic heart failure. Peptides 2012 Oct; 37(2):258-62. doi: 10.1016/j. peptides.2012.08.003 PMID: 22902597
46. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003 Sep 26; 278(39):37419-26. PMID: 12874285
47. Li G, Oparil S, Kelpke SS, Chen YF, Thompson JA. Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation 2002 Aug 13; 106(7):854-9. PMID: 12176960
48. Yoo SH, Huh YH, Hur YS. Inositol 1,4,5-trisphosphate receptor in chromaffin secretory granules and its relation to chromogranins. Cell Mol Neurobiol 2010 Nov; 30(8):1155-61. doi: 10.1007/s10571-010-9564-2 PMID: 21046461
49. D'amico MA, Ghinassi B, Izzicupo P, Manzoli L, Di Baldassarre A. Biological function and clinical relevance of chromogranin A and derived peptides. Endocr Connect 2014 Apr 29; 3(2):R45-R54. doi: 10. 1530/EC-14-0027 PMID: 24671122
50. Angelone T, Mazza R, Cerra MC. Chromogranin-A: a multifaceted cardiovascular role in health and disease. Curr Med Chem 2012; 19(24):4042-50. PMID: 22834795
51. Wu C, Kato TS, Pronschinske K, Qiu S, Naka Y, Takayama H, et al. Dynamics of bone turnover markers in patients with heart failure and following haemodynamic improvement through ventricular assist device implantation. Eur J Heart Fail 2012 Dec;%2012 Sep 18.
52. Wang L, Yuan T, Du G, Zhao Q, Ma L, Zhu J. The impact of 1,25-dihydroxyvitamin D3 on the expression of connective tissue growth factor and transforming growth factor-beta1 in the myocardium of rats with diabetes. Diabetes Res Clin Pract 2014 May; 104(2):226-33. doi: 10.1016/j.diabres.2014.01.031 PMID: 24613393
53. Dong J, Wong SL, Lau CW, Lee HK, Ng CF, Zhang L, et al. Calcitriol protects renovascular function in hypertension by down-regulating angiotensin II type 1 receptors and reducing oxidative stress. Eur Heart J 2012 Dec; 33(23):2980-90. doi: 10.1093/eurheartj/ehr459 PMID: 22267242
54. Lemmila S, Saha H, Virtanen V, Ala-Houhala I, Pasternack A. Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Am J Nephrol 1998; 18(5):404-10. PMID: 9730564
55. Selektor Y, Ahokas RA, Bhattacharya SK, Sun Y, Gerling IC, Weber KT. Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism. Am J Med Sci 2008 Feb; 335(2):105-10. doi: 10.1097/MAJ.0b013e318134f013 PMID: 18277117
56. Carbone LD, Cross JD, Raza SH, Bush AJ, Sepanski RJ, Dhawan S, et al. Fracture risk in men with congestive heart failure risk reduction with spironolactone. J Am Coll Cardiol 2008 Jul 8; 52(2):135-8. doi: 10.1016/j.jacc.2008.03.039 PMID: 18598893